Adirondack Trust Co. lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,487 shares of the company’s stock after selling 300 shares during the period. Adirondack Trust Co.’s holdings in Eli Lilly and were worth $698,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Joel Isaacson & Co. LLC grew its position in Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after acquiring an additional 50 shares during the period. Sumitomo Life Insurance Co. grew its position in Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after acquiring an additional 1,370 shares during the period. Russell Investments Group Ltd. grew its position in Eli Lilly and by 7.8% during the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after acquiring an additional 48,706 shares during the period. Renaissance Technologies LLC grew its position in Eli Lilly and by 93.6% during the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after acquiring an additional 1,441,200 shares during the period. Finally, Stephens Inc. AR grew its position in Eli Lilly and by 4.5% during the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after acquiring an additional 1,901 shares during the period. 75.72% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/adirondack-trust-co-lowers-holdings-in-eli-lilly-and-company-lly/1614327.html.

Eli Lilly and Company (NYSE LLY) opened at 87.08 on Friday. The company has a 50 day moving average price of $82.21 and a 200 day moving average price of $82.15. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The firm has a market cap of $91.87 billion, a PE ratio of 37.68 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the business posted $0.86 earnings per share. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.

A number of equities research analysts have issued reports on the company. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a research report on Friday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday. Cowen and Company restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets restated a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a research note on Thursday, September 28th. Finally, Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a research note on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $88.42.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.